15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $160M | -$546M | 28.6% | -346.2% | -$114M | — | $64M |
| 2024 | $154M | -$310M | 24.2% | -308.0% | -$212M | — | $55M |
| 2023 | $201M | -$307M | 26.3% | -166.8% | -$268M | — | $180M |
| 2022 | $128M | -$314M | 38.2% | -239.4% | -$280M | $899M | $325M |
| 2021 | $131M | -$181M | 45.1% | -161.2% | -$117M | $898M | $461M |
| 2020 | $79M | $29M | 41.3% | -132.3% | $18M | — | $82M |
| 2019 | $91M | -$84M | 38.0% | -110.6% | -$81M | $16M | $30M |
| 2018 | $79M | -$103M | 31.9% | -128.4% | -$68M | $15M | $19M |
| 2017 | $93M | -$92M | 37.1% | -96.1% | -$78M | $14M | $17M |
| 2016 | $91M | -$74M | 48.7% | -78.5% | -$76M | $16M | $17M |
| 2015 | — | -$32M | — | — | — | — | $34M |
| 2014 | — | -$66M | — | — | — | $14M | $36M |
| 2013 | — | -$79M | — | — | -$31M | $13M | $26M |
| 2012 | — | -$94M | — | — | -$79M | $3M | $47M |
| 2011 | — | -$109M | — | — | -$112M | $3M | $59M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $37M | -$8M | 34.5% | -22.5% | -$48M | — | $56M |
| Dec '25 | — | -$40M | — | — | -$20M | — | $64M |
| Sep '25 | $38M | -$38M | 41.4% | -101.1% | -$19M | — | $56M |
| Jun '25 | $40M | -$42M | 36.9% | -112.8% | -$30M | — | $55M |
| Mar '25 | $37M | -$426M | -3.7% | -1154.5% | -$45M | — | $59M |
| Dec '24 | — | $2M | — | — | -$32M | — | $55M |
| Sep '24 | $40M | -$61M | 25.0% | -160.3% | -$45M | — | $78M |
| Jun '24 | $36M | -$173M | 16.5% | -488.3% | -$56M | — | $100M |
| Mar '24 | $39M | -$78M | 29.1% | -209.6% | -$80M | — | $77M |
| Dec '23 | — | -$82M | — | — | -$60M | — | $180M |
| Sep '23 | $56M | -$67M | 32.1% | -148.1% | -$66M | — | $386M |
| Jun '23 | $48M | -$70M | 32.7% | -153.8% | -$44M | — | $209M |
| Mar '23 | $39M | -$88M | 25.1% | -234.6% | -$98M | $897M | $354M |
| Dec '22 | — | -$84M | — | — | -$65M | $899M | $325M |
| Sep '22 | $32M | -$77M | 41.9% | -230.9% | -$67M | $897M | $304M |
| Jun '22 | $35M | -$71M | 45.7% | -191.6% | -$65M | $896M | $310M |
| Mar '22 | $33M | -$81M | 42.7% | -233.7% | -$83M | $896M | $429M |
| Dec '21 | — | -$69M | — | — | -$35M | $898M | $461M |
| Sep '21 | $35M | $17M | 44.0% | -213.5% | -$42M | $896M | $425M |
| Jun '21 | $31M | -$41M | 44.9% | -122.7% | -$17M | $896M | $460M |
How the market has priced PACB against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Pacific Biosciences Of California, Inc.'s revenue has grown 15.2% per year. These are computed facts, not advice.
As of FY2025, Pacific Biosciences Of California, Inc. reported — of total debt against $64M of cash; operating income covered interest expense -79.6×.
In FY2025, gross margin was 28.6%, operating margin -346.2%, and net margin -341.5%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.